Daratumumab for Patients With Light Chain Amyloidosis
Daratumumab for Patients With Light Chain Amyloidosis
Recruiting · NCT06376214 · Registry updated 2024-04-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Daratumumab for Patients With Light Chain Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Not applicable | 2024-04-19 | NCT06376214 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing University School of Medicine | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Clinical Research Center for Kidney Diseases, Jinling Hospital | Nanjing | China | 1 |